Stealthy catheter developer Route 92 Medical, which is developing a catheter to treat stroke, last week said it raised nearly $13 million in an equity round.
Founded in 2015, San Mateo, Calif.-based Route 92 won 510(k) clearance from the FDA a year ago for a percutaneous catheter. The company holds U.S. patents for treating acute ischemic stroke, a rapid aspiration thrombectomy system and intra-cerebral implant delivery.
According to regulatory filings, Route 92 first drummed up $5.9 million in May 2016. Just less than a year later the company doubled that raise, adding another $4.7 million in August 2018. Including the most-recent May 25 filing, Route 92 Medical has raised $29.5 million in equity rounds.
Deep in stealth mode, the company’s website lists only its address and a contact form. Its founder and CEO is Tony Chou, who is also a general partner at the Vertical Group, according to his LinkedIn profile.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.